Texas Instruments' Q1 beat and full-year guidance set up a second-half revenue trajectory that pushes run-rate EPS above $9—a normalization path the market started pricing April 30.
Texas Instruments' Q1 beat and full-year guidance set up a second-half revenue trajectory that pushes run-rate EPS above $9—a normalization path the market started pricing April 30.
A standard blood draw at a hospital-affiliated lab and the same draw at a stand-alone facility like Quest Diagnostics or Labcorp produce identical results....